A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

Exclusion Criteria

• •have a diagnosis of Acute Promyelocytic Leukemia (APL) as defined by the WHO
• •currently participating in or has participated in a study of an investigational agent or device within 4 weeks of treatment initiation
• •have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to treatment initiation
• •have prior monoclonal antibody within 4 weeks prior to study Day 1 or have not recovered from adverse events due to agents administered more than 4 weeks earlier
• •have prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 have not recovered from adverse events due to previously administered agent(s)
• •have a known additional malignancy that is progressing or requires active treatment except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
• •have known active central nervous system (CNS) involvement
• •have an active autoimmune disease requiring systemic treatment within the past 3 months
• •has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
• •have an uncontrolled, life-threatening active infection
• •have a history or current evidence of condition, therapy, or laboratory abnormality that would preclude study participation in the opinion of the treating investigator
• •have known psychiatric or substance abuse disorders that would interfere with cooperation with the trial requirements
• •is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
• •have received prior therapy with any antibody targeting the T-cell co-stimulation or checkpoint pathways
• •have a known history of HIV
• •have known active Hepatitis B or Hepatitis C
• •have received a live vaccine within 30 days prior to treatment initiation